Menu closed

For Patients
For Healthcare Providers
Contact Us

Lilly Oncology Support Center Sitemap

For Patients

For Patients Home

ALIMTA^® (pemetrexed for injection)
CYRAMZA^® (ramucirumab)
ERBITUX^® (cetuximab)
Portrazza^® (necitumumab)
Retevmo^® (selpercatinib)
Verzenio Continuous Care^™ Support Program

For Healthcare Providers

For Healthcare Providers Home

ALIMTA^® (pemetrexed for injection)
CYRAMZA^® (ramucirumab)
ERBITUX^® (cetuximab)
Retevmo^® (selpercatinib)
Verzenio^® (abemaciclib)
Support and Resources

Prescribing Information for ALIMTA^® (pemetrexed for injection)

Patient Prescribing Information for ALIMTA^® (pemetrexed for injection)

Prescribing Information for CYRAMZA^® (ramucirumab)

Prescribing Information for ERBITUX^® (cetuximab), including BOXED WARNING

Prescribing Information for Portrazza^® (necitumumab), including BOXED WARNING

Prescribing Information for Retevmo^® (selpercatinib)

Patient Prescribing Information for Retevmo^® (selpercatinib)

Prescribing Information for Verzenio^® (abemaciclib)

Patient Prescribing Information for Verzenio^® (abemaciclib)

Privacy Statement

Accessibility Statement

To speak to customer support:
Call 1-866-472-8663
Monday - Friday, 8am — 10pm ET

This site is intended for US residents ages 18 and over.

PP-OC-US-0369 10/2021 ©Lilly USA, LLC 2021. All rights reserved.

ALIMTA^®, CYRAMZA^®, ERBITUX^®, Portrazza^®, Retevmo^®, and Verzenio^® are registered trademarks and Verzenio Continuous Care^™ is a trademark owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

Other product/company names mentioned herein are the property of their respective owners.

Terms of Use Privacy Statement Accessibility Statement Sitemap